Immix Biopharma completes NEXICART-2 enrollment; topline results Q3 2026

Immix Biopharma, Inc.

Enrollment complete for 40-patient BLA-enabling Phase 2 trial NEXICART-2 (NCT06097832) in relapsed/refractory AL Amyloidosis.
Topline results expected Q3 2026, followed by BLA submission and planned commercial launch for NXC-201.
Onboarded Chief Medical Officer Richard Graydon, MD, PhD, formerly of Merck and Johnson & Johnson.
NXC-201 has FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations; market for AL Amyloidosis estimated at $6B in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.